| Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up. | |
| | |
MedLine Citation:
|
PMID: 1927853 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The use of oral propafenone was assessed in 57 children. Mean age was 4.8 +/- 5.2 years (range 1 day to 17 years). Twenty-three patients were less than 1 year of age (40%) and 10 were less than 1 month of age (18%). Arrhythmias included supraventricular tachycardia in 32 patients (57%), atrial flutter in six (10%), and ventricular tachycardia in 19 (33%). Cardiac diagnoses included: an otherwise normal heart in 30 (53%); unoperated congenital heart defect in 11 (19%); cardiomyopathy in nine (16%); and an operated congenital heart defect in seven (12%). Mean dose of propafenone was 13.1 mg/kg/day (range 8 to 15). Success (assessed by relief of symptoms and serial 24-hour ECGs) was achieved in 16 of 32 patients with supraventricular tachycardia (50%), three of six with atrial flutter (50%), and 8 of 19 with ventricular tachycardia (42%). Drug efficacy in patients with and without organic heart disease was 30% (8 of 27) and 63% (19 of 30), respectively (p less than 0.05). Mean duration of therapy in patients in whom the drug was effective was 22.9 +/- 13.2 months (range 6 to 60). Growth was unimpaired in all patients. A neonate with nonsustained monomorphic ventricular tachycardia had sustained ventricular tachycardia during the second day of propafenone therapy at a dose of 13 mg/kg/day. Sustained ventricular tachycardia disappeared when the drug was discontinued. Another patient had an asymptomatic and transient increase in the glutamic pyruvic transaminase level. No adverse hemodynamic effects were observed. In conclusion, propafenone is an effective antiarrhythmic drug in children with normal hearts; it is less effective in patients with heart disease.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
P Guccione; F Drago; R M Di Donato; M P Cicini; L Pasquini; B Marino; C Marcelletti; P Ragonese |
Related Documents
:
|
1729853 - Efficacy and electrophysiologic effects of oral sotalol in patients with sustained vent... 1529903 - The prevalence of proarrhythmic events during moricizine therapy and their relationship... 12426513 - Pharmacokinetics of c1-inhibitor protein in patients with acute myocardial infarction. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American heart journal Volume: 122 ISSN: 0002-8703 ISO Abbreviation: Am. Heart J. Publication Date: 1991 Oct |
Date Detail:
|
Created Date: 1991-10-31 Completed Date: 1991-10-31 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1022-7 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesu Hospital, Rome, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Arrhythmias, Cardiac / diagnosis, drug therapy*, etiology Atrial Flutter / drug therapy Chi-Square Distribution Child Child, Preschool Follow-Up Studies Heart Defects, Congenital / complications Humans Infant Infant, Newborn Propafenone / administration & dosage, adverse effects, therapeutic use* Tachycardia / drug therapy |
| Chemical | |
Reg. No./Substance:
|
54063-53-5/Propafenone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe h...
Next Document: Assessment of right ventricular diastolic and systolic function in patients with dilated cardiomyopa...